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Leiden, The Netherlands
This brief review will summarise our present knowl-
edge on the possible role of human minor histocom-
patibility antigens (mHags) in graft failure. Following
a short introduction on the possible nature of human
mHags some in vitro studies dealing with graft failure
and rejection will be discussed. To understand the
possible impact of mHag disparity between organ
donor and recipient on the outcome of organ and
bone marrow (BM) grafting, Information on their
tissue expression is essential; hence a summary is
given on the mHag tissue distribution studies
performed so far. Finally, we will present our
preliminary studies on the expression of mHag on
human corneal tissue.
POSSIBLE NATURE OF HUMAN mHag
mHags are most probably naturally processed
peptides of cytosolic proteins.1'2 The MHC
restricted presentation of mHag peptides on the
cell surface requires peptide import by an ABC
transporter dependent system into the endoplasmic
reticulum, where they bind to newly sensitised MHC
molecules.3 In the clinical setting of organ and BM
transplantation between HLA matched, mHags
mismatched individuals, the mHags are capable of
inducing vigorous immune responses leading to graft
rejection or graft-versus-host disease.4"6 The male-
specific H-Y is by far the simplest and also the most
extensively studied mHag The first report on H-Y as
a transplantation antigen is an untitled communica-
tion by Eichwald and Silmser in 1955. These authors
observed that within two inbred strains of mice, most
of the male-to-female skin grafts were rejected,
whereas transplants made in other sex combinations
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nearly always succeeded.7 The term H-Y antigen was
introduced by Billingham and Silvers because the
male-speciflc antigen can function as a classical
transplantation antigen responsible for homograft
rejection.8
mHag AND GRAFT FAILURE: SOME
RELATED CLINICAL STUDIES
In the human Situation the first report on involve-
ment of H-Y in transplantation appeared in 1976.9 It
concerned a clinical observation of rejection of a BM
graft from a male sibling by his HLA-identical sister.
In vitro analysis of the post-transplant peripheral
blood lymphocytes (PBLs) of this female patient
(HLA phenotype: HLA-A2, -A2, -B44, -B60, -Cw3,
-Cw5, -DR4, -Drw6) showed unambiguously strong
cytotoxic Τ cell (CTL) responses specific for male
HLA-A2 positive target cells.9·10 Whether the H-Y
specific CTLs actually mediated the allograft rejec-
tion, we do not know. It must be remarked, however,
that most probably the female patient, who suffered
from severe aplastic anaemia, had been sensitised to
the H-Y antigen prior to BM transplantation through
multiple, mainly male, blood transfusions and
pregnancies. This assumption is based on our
subsequent observations. As shown in Table I,
PBLs derived from four additional cases showed,
after in vitro restimulation with HLA-identical male
cells, exactly the same phenomenon, namely HLA
restricted (-AI, -A2 and/or -B7) anti-H-Y CTL
activity. In one patient (i.e. case 5, Table I), the
H-Y specific HLA-B7 restricted cytotoxicity was
detected shortly after an acutely rejected kidney
donated by an HLA-identical male sibling (unpub-
lished observation). In circumstances similar to ours,
other investigators also described the presence of
HLA restricted H-Y directed cytotoxicity.1112
Although in our first case we could not formallv
prove that the H-Y specific CTLs actually mediated
the rejection of the male BM allograft, some years
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• Table I. MHC restricted cytotoxicT cell (CTL) responses against the mHag H-Y
Patient/diseasea CTLs CTL specificity
1. AA
2. AA
3. AA
4. AA
5. Kidney failure
gost BM grafting
Multitransfused
Multitransfused
Multitransfused
Post renal transplant
HLA-A2 H-Y
HLA-A2 H-Y
HLA-A2 H-Y/HLA-B7 H-Y
HLA-Al H-Y
HLA-B7 H-Y
AA, aplastic anaemia; BM, bone marrow.
a
 All patients were female.
ago we were confronted with a case with a fatal
outcome in which anti-H-Y CTLs were most
probably mainly responsible for BM graft failure. It
concerned a multitransfused female patient suffering
from myelodysplasia after treatment for Hodgkin's
disease. In vitro analysis prior to BM transplantation
demonstrated the presence of HLA-Al restricted
anti-H-Y CTLs (Table I, case 4). Since the father
appeared to be the only HLA compatible related
donor, he was the obvious choice (despite the
presence of the patient's pretransplant anti-H-Y
CTLs). Notwithstanding intensive pretransplant
immunosuppressive treatment and the donation of
Τ cell depleted marrow, there was no recovery of the
bone marrow haematopoietic function.13 In view of
the latter case, expression of mHag on haematopoie-
tic stem cells (HPC) might be relevant in presensi-
tised patients receiving a mHag-positive Τ cell
depleted marrow graft. For that purpose, the
expression of the male specific antigen H-Y was
studied for its expression on HPC. It became clear
that indeed H-Y is expressed on CFU-GEMM, CFU-
GM and BFU-E.14 Experiments carried out to study
the expression of other (non-sex-linked) mHag
(designated HA-1 to HA-5), demonstrated expres-
sion of all the latter antigens on HPC. 1 4 ' 1 5
The clinical relevance of the H-Yalloantigen in the
context of HLA-A2 to the results of human kidney
allograft transplantation has also been determined. Α
retrospective study showed that HLA-A2 females
receiving HLA-A2 male kidneys survived for a
significantly shorter time than did non-HLA-A2
male kidneys in non-HLA-A2 female recipients.16
mHag TISSUE DISTRIBUTION STUDIES
Naturally the impact of mHags on the outcome of
organ and BM grafting is dependent on, amongst
other things, their tissue distribution. Table II
summarises the tissues and cells studied to date. We
observed ubiquitous versus restricted tissue distribu-
tion of the mHags analysed.17 Expression of the non-
sex-linked mHags, i.e. HA-1, -2 and -5,17 is restricted
to the haematopoietic cell lineage including epider-
mal-derived Langerhans cells,18 whereas H-Y, HA-3
and HA-4 were found to be expressed on cells of all
tissues tested (see Table II).
The contribution of mHags to the cascade of
inflammatory events, especially in cutaneous allo-
graft rejection, is largely dependent on which type of
antigen presenting cell (APC) the antigen is
presented on. Namely, Τ cells can be inactivated
instead of activated when occupation of their Τ cell
receptor (TCR) by antigen is not accompanied by
appropriate co-stimulatory signal(s) ,1 9 This so-
called State of Τ cell anergy is marked by unrespon-
siveness to subsequent adequate triggering by
Professional APC and can be induced in several
19
ways. Keratinocytes, fibroblasts, and many other
Table II. Tissue distribution of human minor histocompatibility antigens
HA4 HA-2 HA-3 H-Y HA-4 HA-5
Haematopoietic stem cells
Thymocytes
Peripheral blood lymphoctyes
PBL blasts
EBV BLCL
Monocytes
Dendritic cells
Leukaemic cells
Myeloid
Lymphocytic
Langerhans cells (skin)
Fibroblasts
Keratinocytes
Melanocytes
Melanomas
Cord endothelial cells
Kidney proximal tubular epithelium cells
HA-1
HA-1
HA-1
HA-1
HA-1
HA-1
HA-1
HA-1
HA-1
HA-1
HA-2
HA-2
' HA-2
HA-2
HA-2
HA-2
HA-2
HA-2
HA-2
HA-2
HA-3
n.t.
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
HA-3
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
H-Y
HA-4
n.t.
HA-4
HA-4
HA-4
HA-4
HA-4
HA-4
HA-4
HA-4
n.t.
HA-4
HA-4
HA-5
n.t.
HA-5
HA-5
HA-5
HA-5
HA-5
HA-5
HA-5
n.t.
PBL, peripheral blood lymphocytes; EBV BLCL, Epstein-Barr virus Β lymphoblastoid cell line; n.t., not tested.
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Table III. mHag expression
Cornea donora HLA type
on human corneal tissue: preliminary
/liHYb
results
mHag
Λ/ΗΑ-3
specific clones
A2H-Y B7H-Y
Experiment 1
HLA-A3 (F)
HLA-Al (M)
HLA-B7 (M)
Experiment 2
0
0
n.t.
n.t.
36
n.t.
n.t.
n.t.
n.t.
Τ
n.t.
16
HLA-Al
HLA-Al
(M)
(F)
Experiment 3
HLA-Al (M)
HLA-A2 (M)
14
0
HLA-/l/d
59
n.t.
47
32
HLA specific and
A1HA-3
45
n.t.
n.t.
n.t.
mHag specific clones
HLA-A2
n.t.
45
n.t.
n.t.
A2H-Y
n.t.
71
(M), male; (F), female; n.t., not tested.
''Corneal scleral tissue incubated with 200 U/ml IFN7 for 48 hours, trypsinised, resuspended and used as target cells in the cell mediated
lympholysis (CML) assay.17
b
mHag specific CTL clones are used as effector cells. The mHag HY can be recognised in the context of different HLA molecules (see
Table 1 and ref. 4). The recognition of mHag HA-3 is restncted to HLA-Al.4
cPercentage specific lysis in the CML assay: <10% is negative, >11% is scored as positive.
dHLA specific CTL clones used in this study are directed against the HLA molecules HLA-Al and HLA-A2.
so-called non-classical APC 2 0 have been found to
have no or little capacity of Τ cell activation, even
after interferon-gamma induced HLA class II
expression.2122 HLA class II expressing keratino-
cytes (also found in a GVHD-affected skin,20 were
even found to tolerise hapten-specific Τ cell clones in
vitro.23
The expression of mHag on non-classical APCs,
such as HA-3 on keratinocytes, could play a role in
the induction of BM transplantation tolerance. We
earlier investigated the development of acquired
tolerance for rnHag HA-3 in a healthy chimaeric BM
recipient 7 years after HLA-identical but HA-3
mismatched BMT.24 We found persistent host
specific HA-3 expression on patient's skin tissue
after BM transplantation together with disappear-
ance of anti-host HA-3 CTLs which paralleled the
in vivo State of tolerance. We hypothesised, there-
fore, that direct presentation of host mHags by
parenchymal host tissues funclioning as non-classical
or inadequate APC could result in tolerisation of
anti-host CTLs induced following BM engraftment.24
According to this hypothesis, the induction of long-
term graft-host tolerance versus graft-host reactivity
after BM transplantation across mHags barriers
would depend on the tissue distribution of the
mHags in question.
Similarly, the need for adequate Signals for Τ cell
activation and subsequent murine corneal allograft
rejection was earlier put forward by Chandler et al.25
Indeed, inadequate presentation of the mHag H-Y in
a murine cornea model led to a specific State of
unresponsiveness to H-Y.26 On the other hand when
the corneal graft, which is normally devoid of
Langerhans cells (LC), became infiltrated with
donor-derived LC through graft pretreatment with
latex beads, rejection of mHag-disparate corneal
grafts was observed.27 Although, as discussed above,
keratinocytes are not capable of inducing primary Τ
cell activation, they do have limited capacity to
activate memory Τ cells.28 In this context it is of
importance to note that allogeneic corneas that were
transplanted into eyes of presensitised mice were
uniformly subjected to an acute rejection process.29
With regard to the role of mHag in the latter study, it
was shown that the highest rate of rejection occurred
among grafts that confronted their hosts with
multiple mHag, with or without major histocompat-
ibility antigens.29
mHag EXPRESSION ON HUMAN CORNEAL
TISSUE: PRELIMINARY RESULTS
It is well known that corneal tissue recipients do
benefit from an HLA matched graft,30 especially the
high-risk patients.31 Even in those HLA matched
cases, corneal graft survival, after excluding the non-
immunological causes for graft failure, is well below
100%.32 Since HLA antigens are expressed on
corneal tissue,33 it would, in view of their character-
istics, not be surprising that mHags will coexist as
well. To elaborate on the latter assumption, we
recently started to analyse the functional expression
of human mHags on corneal scleral tissue. Our well-
defined CTL clones specific major HLA antigens
HLA-Al and HLA-A2 and for the mHag H-Y (see
Table I) and for the non-sex-Iinked mHag HA-34
were used as effector cells in cell mediated
lympholysis (CML) assays. As target cells, trypsi-
nised corneal scleral tissues were used. Table III
demonstates the results of our first small series of
experiments. Both HLA antigens and mHag H-Y
and HA-3 are readily detectable on corneal tissue;
they function as target molecules for CTL clones.
These observations are in agreement with our earlier
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^studies on the broad mHag tissue expression of H-Y
and HA-3. Likewise, it is to be expected (Table II),
but has yet to be proven, that all mHag we can test
for to date are expressed on LCs^residing in the
corneal epithelium. This knowledge is especially
important in view of the LC's characteristic as an
adequate APC.
We demonstrate here for the first time, to our
Knowledge, me functional expression of mHags on
human corneal tissue. Naturally these limited data
need confirmation and extension. The present studies
may bring us closer to understanding the impact of
mHag mismatching between corneal graft donor and
recipient in the human Situation. The role of mHag
disparities, in especially presensitised recipients, was
recently clearly demonstrated in a murine study.29
Encouraged by the latter data we feel it is justified to
continue our search for mHags on corneal tissue and
their possible role in the outcome of corneal grafting.
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